MedTrace Logo

ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

NCT00283361 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2007-02-28

No results posted yet for this study

Summary

The main purpose of this study is to see if the experimental drug ZP120, when given with the approved drug furosemide to patients with acute or sub-acute heart failure, can reduce the amount of fluid in the patients' lungs and make breathing easier.

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

ZP120

PROCEDURE

I.v. catherization

PROCEDURE

6-minutes walk performance

BEHAVIORAL

Dyspnea severity assessment

PROCEDURE

Blood sampling for laboratory tests

PROCEDURE

ECG

PROCEDURE

Physical examination

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283361 on ClinicalTrials.gov